

## WHAT IS CLAIMED IS:

1. A method for treating or preventing gastritis in a subject, comprising administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin.
2. A method for treating or preventing gastric ulceration in a subject, comprising administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin.
3. A method of treating or preventing pain, fever, inflammation, arthritis, hypercoagulability, or other condition for which a non-steroidal anti-inflammatory agent would be indicated, comprising administering to subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin, and a therapeutically effective amount of a non-steroidal anti-inflammatory agent.
4. A method of enhancing the analgesic activity of a non-steroidal anti-inflammatory drug in a subject, comprising administering an amylin or an amylin agonist along with said non-steroidal anti-inflammatory drug, wherein said amylin agonist is not a calcitonin.
5. The method according to any of claims 1-4, wherein said subject is human.
6. The method according to any of claims 1-4, wherein said amylin or amylin agonist is administered by a route selected from the group consisting of nasal, oral, pulmonary, transdermal, and buccal administration.
7. The method according to any of claims 1-4 wherein said amylin agonist is selected from the group consisting

of <sup>18</sup>Arg<sup>25,28</sup>Pro-h-amylin, des-<sup>1</sup>Lys<sup>18</sup>Arg<sup>25,28</sup>Pro-h-amylin, <sup>18</sup>Arg<sup>25-28,29</sup>Pro-h-amylin, des-<sup>1</sup>Lys<sup>18</sup>Arg<sup>25,28,29</sup>Pro-h-amylin, <sup>25,28-29</sup>Pro-h-amylin, des-<sup>1</sup>Lys<sup>25,28,29</sup>Pro-h-amylin, <sup>25</sup>Pro<sup>26</sup>Val<sup>28,29</sup>Pro-h-amylin, <sup>23</sup>Leu<sup>25</sup>Pro<sup>26</sup>Val<sup>28,29</sup>Pro-h-amylin, <sup>23</sup>Leu<sup>25</sup>Pro<sup>26</sup>Val<sup>28</sup>Pro-h-amylin, 5 des-<sup>1</sup>Lys<sup>23</sup>Leu<sup>25</sup>Pro<sup>26</sup>Val<sup>28</sup>Pro-h-amylin, <sup>18</sup>Arg<sup>23</sup>Leu<sup>25</sup>Pro<sup>26</sup>Val<sup>28</sup>Pro-h-amylin, <sup>18</sup>Arg<sup>23</sup>Leu<sup>25,28,29</sup>Pro-h-amylin, <sup>18</sup>Arg<sup>23</sup>Leu<sup>25,28</sup>Pro-h-amylin, <sup>17</sup>Ile<sup>23</sup>Leu<sup>25,28,29</sup>Pro-h-amylin, <sup>17</sup>Ile<sup>25,28,29</sup>Pro-h-amylin, des-<sup>1</sup>Lys<sup>17</sup>Ile<sup>23</sup>Leu<sup>25,28,29</sup>Pro-h-amylin, <sup>17</sup>Ile<sup>18</sup>Arg<sup>23</sup>Leu-h-amylin, <sup>17</sup>Ile<sup>18</sup>Arg<sup>23</sup>Leu<sup>26</sup>Val<sup>29</sup>Pro-h-amylin, <sup>17</sup>Ile<sup>18</sup>Arg<sup>23</sup>Leu<sup>25</sup>Pro<sup>26</sup>Val<sup>28,29</sup>Pro-h-amylin, <sup>13</sup>Thr<sup>21</sup>His<sup>23</sup>Leu<sup>26</sup>Ala<sup>28</sup>Leu<sup>29</sup>Pro<sup>31</sup>Asp-h-amylin, <sup>13</sup>Thr<sup>21</sup>His<sup>23</sup>Leu<sup>26</sup>Ala<sup>29</sup>Pro<sup>31</sup>Asp-h-amylin, des-<sup>1</sup>Lys<sup>13</sup>Thr<sup>21</sup>His<sup>23</sup>Leu<sup>26</sup>Ala<sup>28</sup>Pro<sup>31</sup>Asp-h-amylin, <sup>13</sup>Thr<sup>18</sup>Arg<sup>21</sup>His<sup>23</sup>Leu<sup>26</sup>Ala<sup>29</sup>Pro<sup>31</sup>Asp-h-amylin, 15 <sup>13</sup>Thr<sup>18</sup>Arg<sup>21</sup>His<sup>23</sup>Leu<sup>28,29</sup>Pro<sup>31</sup>Asp-h-amylin, and <sup>13</sup>Thr<sup>18</sup>Arg<sup>21</sup>His<sup>23</sup>Leu<sup>25</sup>Pro<sup>26</sup>Ala<sup>28,29</sup>Pro<sup>31</sup>Asp-h-amylin.

8. The method according to any of claims 1-4, wherein said amylin agonist is <sup>25,28,29</sup> Pro-h-amylin.

15 9. The method according to any of claims 1 or 2, wherein said gastritis or gastric ulceration is associated with the administration of a non-steroidal anti-inflammatory drug.

10. The method according to any of claims 3 or 4 wherein said non-steroidal anti-inflammatory agent is 25 selected from the group consisting of salicylate, phenylbutazone, indomethacin, acetaminophen, phenacetin, naproxen and ibuprofen.

11. A pharmaceutical composition comprising (1) an amylin or an amylin agonist, or a pharmaceutically 30 acceptable salt thereof, wherein said amylin agonist is not

a calcitonin, and (2) a non-steroidal anti-inflammatory agent, in a pharmaceutically acceptable carrier and dose.

12. The pharmaceutical composition according to claim 11, wherein said non-steroidal anti-inflammatory agent is  
5 selected from the group consisting of salicylate, phenylbutazone, indomethacin, acetaminophen, phenacetin, naproxen, and ibuprofen.

add  
but

add  
a2

add  
a2